Phase I/II Study of Lenalidomide (Revlimid), Thalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 06 Jul 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
- 30 Nov 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.